Teratologic assessment of maleic hydrazide and daminozide, and formulations of ethoxyquin, thiabendazole and naled in rats.
Teratogenicity studies were conducted in rats treated orally from days 6-15 of gestation with single daily doses of 400-1600 mg/kg of maleic hydrazide, 300-1000 mg/kg daminozide, 125-500 mg/kg ethoxyquin or thiabendazole, or 25-100 mg/kg naled. Dams were killed on the 22nd day of gestation, and fetuses were evaluated by routine teratologic methods. No adverse effect was related to any treatment other than an increased incidence of anomalous fetuses at the highest dose (500 mg/kg) of thiabendazole.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D005015:Ethoxyquin / Q000633:toxicity*; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D007306:Insecticides / Q000633:toxicity*; D008300:Maleic Hydrazide / Q000633:toxicity*; D009267:Naled / Q000633:toxicity*; D010937:Plant Growth Regulators / Q000633:toxicity*; D011247:Pregnancy; D011724:Pyridazines / Q000633:toxicity*; D011804:Quinolines / Q000633:toxicity*; D051381:Rats; D013386:Succinates / Q000633:toxicity*; D013723:Teratogens; D013827:Thiabendazole / Q000633:toxicity*
D007306:Insecticides; D010937:Plant Growth Regulators; D011724:Pyridazines; D011804:Quinolines; D013386:Succinates; D013723:Teratogens; D005015:Ethoxyquin; D013827:Thiabendazole; D009267:Naled; D008300:Maleic Hydrazide